Cancer Clinical Trial
Official title:
A Phase 1, Multicenter, Open-label, Dose-escalation Study to Evaluate the Safety, Tolerability and PK/PD of Recombinant Anti-EpCAM and Anti-CD3 Human-Mouse Chimeric Bispecific Antibody Via Intraperitoneal Infusion in Malignant Ascites
This study is to investigate the safety, tolerability, PK, PD and immunogenicity of multiple ascending doses of M701 administered intraperitoneally to patients with malignant ascites caused by advanced solid tumors.
Status | Recruiting |
Enrollment | 42 |
Est. completion date | June 30, 2021 |
Est. primary completion date | January 31, 2021 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility |
Inclusion Criteria: 1. Males or females, aged > 18 years; 2. Histologically- or cytologically-confirmed advanced solid tumors; 3. Patients who require therapeutic paracentesis, defined as at least 1 therapeutic paracentesis (e.g., to relieve abdominal pressure and discomfort) during 4 weeks prior to the baseline paracentesis; 4. Patients who have failed to standard treatment, or who have no standard treatment available that may confer clinical benefit; 5. EpCAM+ tumor cells in ascites fluid; 6. Patients who have received anti-tumor therapy including chemotherapy, hormone therapy, radiotherapy (except local radiotherapy for pain relief) = 2 weeks or received immunotherapy, biological agents = 3 weeks prior to the first dose of study drug; 7. Patients who have recovered from any toxic reaction to previous medications (Grade 0 or 1 based on NCI-CTCAE v5.0); 8. Patients with an ECOG Performance Status score (PS) 0-3; 9. Patients with a life expectancy > 8 weeks; 10. Organ function levels must meet the following requirements: Bone marrow: absolute neutrophil count (ANC) = 1.5 ×10^9/L, platelet count = 80 ×10^9/L, hemoglobin = 9.0 g/dL (without blood transfusion within14 days of the first dose of study drug); Liver: bilirubin = 1.5 x upper limit of normal (ULN), aspartate aminotransferase (AST) and alanine transaminase (ALT) = 3 x ULN ( = 5 x ULN in case of liver metastases); Kidney: serum creatinine =1.5 x ULN and estimated glomerular filtration rate (eGFR) = 50 ml/min; 11. Patients must understand and voluntarily sign the informed consent form. Exclusion Criteria: 1. Known to have a history of allergy to the active ingredients of M701; or with a definite history of drug allergy or specific allergy (asthma, rubella, eczema dermatitis); 2. Known or suspected hypersensitivity to M701 or similar antibodies; 3. Extensive liver metastases (> 70% organ volume comprises malignancy); 4. Uncontrolled active infection (CTCAE = Grade 2); 5. Serious diarrhea (CTCAE = Grade 2); 6. Serious dyspnea requiring oxygen therapy; 7. History of auto-immune diseases (e.g. inflammatory bowel disease, idiopathic thrombocytopenic purpura, lupus erythematosus, autoimmune hemolytic anemia, scleroderma, serious psoriasis, rheumatoid arthritis); 8. History of acute or chronic pancreatitis; 9. Other serious diseases that may prevent patients participation in this trial (such as uncontrolled diabetes mellitus, severe gastrointestinal disorders); 10. Cardiac insufficiency, NYHA class III or IV; 11. Intestinal obstruction that occurred within 30 days prior to the first dose of study drug; 12. Non-drainable ascites; 13. Confirmed portal vein obstruction; 14. History of immunodeficiency, including positive HIV test; 15. Active hepatitis B virus infection or hepatitis C virus infection, positive syphilis antibody test and positive HIV antibody test; 16. Pregnant or breastfeeding woman; 17. Plan to conceive within six months; 18. Previous confirmed history of neurological or mental disorders, including epilepsy and dementia; 19. Have received a clinical study active drug treatment within 1 month prior to the first dose of study drug; 20. Those that are deemed ineligible for this clinical trial by study personnel. |
Country | Name | City | State |
---|---|---|---|
China | The 307th Hospital of Chinese People's Liberation Army | Beijing | Beijing |
China | Tongji Hospital of Tongji Medical College,Huazhong University of Science and Technology | Wuhan | Hubei |
Lead Sponsor | Collaborator |
---|---|
Wuhan YZY Biopharma Co., Ltd. |
China,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | MTD | Number of DLTs (dose limiting toxicities) during the first 28 days after the first administrations of study drug in each cohort. | From the time of the first dose (Day 1) until the forth dosing (Day 28) | |
Primary | Incidence of AEs | Incidence and severity of AEs, including but not limited to vital signs, physical examination, laboratory tests. All AEs will be classified as Grades 1 through 5 as defined by NCI CTCAE v5.0. | From the start of administration to the end of the study or 28 days after the administration is stopped (up to 6 months and 28 days) | |
Secondary | Area under the curve (AUC) of M701 | The endpoints for assessment of PK of M701 include serum concentrations of M701 at different timepoints after M701 administration. | From the time of first dosing (Day 1) until disease progression or toxicity intolerance (up to 6 months). | |
Secondary | Maximum observed concentration (Cmax) of M701 | The endpoints for assessment of PK of M701 include serum concentrations of M701 at different timepoints after M701 administration. | From the time of first dosing (Day 1) until disease progression or toxicity intolerance (up to 6 months). | |
Secondary | Minimum observed concentration (Cmin) of M701 | The endpoints for assessment of PK of M701 include serum concentrations of M701 at different timepoints after M701 administration. | From the time of first dosing (Day 1) until disease progression or toxicity intolerance (up to 6 months). | |
Secondary | The antibody titer of the neutralizing antibody | The immunogenicity of M701 will be collected by testing the antibody titer of the neutralizing antibody. | From the time of first dosing (Day 1) until disease progression or toxicity intolerance (up to 6 months). | |
Secondary | Number of subjects who develop detectable anti-drug antibodies (ADAs) | The immunogenicity of M701 will be assessed by summarizing the number of subjects who develop detectable anti-drug antibodies (ADAs). | From the time of first dosing (Day 1) until disease progression or toxicity intolerance (up to 6 months). | |
Secondary | Expression levels of CEA | As tumor marker, expression levels of CEA will be tested in each study site. | From the time of screening period until disease progression or toxicity intolerance (up to 6 months and 14 days). | |
Secondary | Expression levels of CA125 | As tumor marker, expression levels of CA125 will be tested in each study site. | From the time of screening period until disease progression or toxicity intolerance (up to 6 months and 14 days). | |
Secondary | Expression levels of CA72-4 | As tumor marker, expression levels of CA72-4 will be tested in each study site. | From the time of screening period until disease progression or toxicity intolerance (up to 6 months and 14 days). | |
Secondary | Expression levels of CA19-9 | As tumor marker, expression levels of CA19-9 will be tested in each study site. | From the time of screening period until disease progression or toxicity intolerance (up to 6 months and 14 days). | |
Secondary | Expression levels of AFP | As tumor marker, expression levels of AFP will be tested in each study site. | From the time of screening period until disease progression or toxicity intolerance (up to 6 months and 14 days). | |
Secondary | Cytokines | The levels of pharmacodynamic cytokines will be determined at the PD central laboratory. | From the time of first dosing (Day 1) until disease progression or toxicity intolerance (up to 6 months). | |
Secondary | Counts of Lymphocyte subsets | Lymphocyte subsets will be determined at the PD central laboratory. | From the time of first dosing (Day 1) until disease progression or toxicity intolerance (up to 6 months). | |
Secondary | Ascites volume | Ascites volume will be collected before each dose. | From the time of first dosing (Day 1) until disease progression or toxicity intolerance (up to 6 months). |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05346796 -
Survivorship Plan HEalth REcord (SPHERE) Implementation Trial
|
N/A | |
Recruiting |
NCT05094804 -
A Study of OR2805, a Monoclonal Antibody Targeting CD163, Alone and in Combination With Anticancer Agents
|
Phase 1/Phase 2 | |
Completed |
NCT04867850 -
Effect of Behavioral Nudges on Serious Illness Conversation Documentation
|
N/A | |
Enrolling by invitation |
NCT04086251 -
Remote Electronic Patient Monitoring in Oncology Patients
|
N/A | |
Completed |
NCT01285037 -
A Study of LY2801653 in Advanced Cancer
|
Phase 1 | |
Completed |
NCT00680992 -
Study of Denosumab in Subjects With Giant Cell Tumor of Bone
|
Phase 2 | |
Completed |
NCT00062842 -
Study of Irinotecan on a Weekly Schedule in Children
|
Phase 1 | |
Active, not recruiting |
NCT04548063 -
Consent Forms in Cancer Research: Examining the Effect of Length on Readability
|
N/A | |
Completed |
NCT04337203 -
Shared Healthcare Actions and Reflections Electronic Systems in Survivorship
|
N/A | |
Recruiting |
NCT04349293 -
Ex-vivo Evaluation of the Reactivity of the Immune Infiltrate of Cancers to Treatments With Monoclonal Antibodies Targeting the Immunomodulatory Pathways
|
N/A | |
Terminated |
NCT02866851 -
Feasibility Study of Monitoring by Web-application on Cytopenia Related to Chemotherapy
|
N/A | |
Active, not recruiting |
NCT05304988 -
Development and Validation of the EFT for Adolescents With Cancer
|
||
Completed |
NCT04448041 -
CRANE Feasibility Study: Nutritional Intervention for Patients Undergoing Cancer Surgery in Low- and Middle-Income Countries
|
||
Completed |
NCT00340522 -
Childhood Cancer and Plexiform Neurofibroma Tissue Microarray for Molecular Target Screening and Clinical Drug Development
|
||
Recruiting |
NCT04843891 -
Evaluation of PET Probe [64]Cu-Macrin in Cardiovascular Disease, Cancer and Sarcoidosis.
|
Phase 1 | |
Active, not recruiting |
NCT03844048 -
An Extension Study of Venetoclax for Subjects Who Have Completed a Prior Venetoclax Clinical Trial
|
Phase 3 | |
Completed |
NCT03167372 -
Pilot Comparison of N-of-1 Trials of Light Therapy
|
N/A | |
Completed |
NCT03109041 -
Initial Feasibility Study to Treat Resectable Pancreatic Cancer With a Planar LDR Source
|
Phase 1 | |
Terminated |
NCT01441115 -
ECI301 and Radiation for Advanced or Metastatic Cancer
|
Phase 1 | |
Recruiting |
NCT06206785 -
Resting Energy Expenditure in Palliative Cancer Patients
|